Assessment of Immune Related Rheumatological Adverse Events in A Monovalent Oncology Center in Argentina | ||
| dc.conicet.organizacion | Universidad de Buenos Aires. Facultad de Medicina. Instituto de Oncología "Ángel H. Roffo" | |
| dc.conicet.organizacion | Consejo Nacional de Investigaciones Científicas y Técnicas | |
| dc.conicet.organizacion | Universidad de Buenos Aires. Facultad de Medicina. Instituto de Oncología "Ángel H. Roffo" | |
| dc.conicet.organizacion | Universidad de Buenos Aires. Facultad de Medicina. Instituto de Oncología "Ángel H. Roffo" | |
| dc.conicet.organizacion | Universidad de Buenos Aires. Facultad de Medicina. Instituto de Oncología "Ángel H. Roffo" | |
| dc.conicet.organizacion | Universidad de Buenos Aires. Facultad de Medicina. Instituto de Oncología "Ángel H. Roffo" | |
| dc.conicet.organizacion | Universidad de Buenos Aires. Facultad de Medicina. Instituto de Oncología "Ángel H. Roffo" | |
| dc.conicet.organizacion | Universidad de Buenos Aires. Facultad de Medicina. Instituto de Oncología "Ángel H. Roffo" | |
| dc.conicet.organizacion | Universidad de Buenos Aires. Facultad de Medicina. Instituto de Oncología "Ángel H. Roffo" | |
| dc.conicet.organizacion | Universidad de Buenos Aires. Facultad de Medicina. Instituto de Oncología "Ángel H. Roffo" | |
| dc.conicet.organizacion | Universidad de Buenos Aires. Facultad de Medicina. Instituto de Oncología "Ángel H. Roffo" | |
| dc.conicet.organizacion | Universidad de Buenos Aires. Facultad de Medicina. Instituto de Oncología | |
| dc.conicet.organizacion | Consejo Nacional de Investigaciones Científicas y Técnicas | |
| dc.contributor.author | Sabio Collado, María Victoria | |
| dc.contributor.author | Gandur, María Natalia | |
| dc.contributor.author | Zerga, Marta Elisa | |
| dc.contributor.author | Cugliari, María Silvana | |
| dc.contributor.author | Castro, Mónica | |
| dc.contributor.author | Cuartero, Viviana | |
| dc.contributor.author | Cáceres, Valeria | |
| dc.contributor.author | Serrano, Laura Marcela | |
| dc.contributor.author | Casas Parera, Ignacio Faustino | |
| dc.contributor.author | Cinat, Gabriela | |
| dc.contributor.author | Ranuncolo, Stella Maris | |
| dc.date.issued | 2025-12 | |
| dc.description.abstract | Background: Immune checkpoint inhibitors (ICIs) have changed the oncology patients´ outcome. They are being used inan increasingly number of different cancers. Consequently, there is enhanced ICIs-associated-toxicity, named immunerelated-adverse-events. Objectives: To define the Immune-related-Rheumatologic-Adverse-Events (IrRAEs) in ICIs treatedoncological patients, determining the oncological treatment continuity following their development. To investigatewhether pre-existing rheumatologic diseases (PRD).explained the ICI-treatment initiation failure. Material and Methods:This descriptive-retrospective study Included 42 oncology patients, initiating or already undergoing ICI treatment, referredto the Rheumatology Department during 2019-2022. Results: 40/159 (25%) patients that received ICI treatment at theRoffo Oncology Institute, were evaluated by the Rheumatology Department. 16/40 experienced IrRAEs [IrRAEs` treatment:5/16 received non-steroidal anti-infammatory drugs, 11/16 corticosteroids (5/11 required additionally Disease-ModifyingAntirheumatic Drugs (DMARDs)]. The IrRAEs treatment outcome was: complete response (9/16), partial response (2/16) andno response (5/16). As a consequence 7/16 patients (44%) continued the ICI therapy, 3/16 (19%) experienced a temporarysuspension and 6/16 (37%) a permanent discontinuation. Two patients didn´t iniciate ICIs due to PRD. Conclusions: 25%of the total ICI treated patients developed rheumatologyc symptoms. The IrRAEs were the cause of them in 16/40 patients.Therefore 10% (16/159) of the total ICI treated patients developed IrRAEs, being most of them mild to moderate. Only onepatient, suffering myositis, experienced a severe life-threatening IrRAE. The patients´ evaluation at the time they startedthe ICI therapy allowed the PRD diagnosis and to monitore exacerbations. Half of the patients who developed IrRAEs werecapable to continue their ICI treatment. | es_ES |
| dc.description.fil | Fil: Sabio Collado, María Victoria. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Oncología "Ángel H. Roffo"; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina | |
| dc.description.fil | Fil: Gandur, María Natalia. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Oncología "Ángel H. Roffo"; Argentina | |
| dc.description.fil | Fil: Zerga, Marta Elisa. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Oncología "Ángel H. Roffo"; Argentina | |
| dc.description.fil | Fil: Cugliari, María Silvana. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Oncología "Ángel H. Roffo"; Argentina | |
| dc.description.fil | Fil: Castro, Mónica. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Oncología "Ángel H. Roffo"; Argentina | |
| dc.description.fil | Fil: Cuartero, Viviana. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Oncología "Ángel H. Roffo"; Argentina | |
| dc.description.fil | Fil: Cáceres, Valeria. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Oncología "Ángel H. Roffo"; Argentina | |
| dc.description.fil | Fil: Serrano, Laura Marcela. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Oncología "Ángel H. Roffo"; Argentina | |
| dc.description.fil | Fil: Casas Parera, Ignacio Faustino. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Oncología "Ángel H. Roffo"; Argentina | |
| dc.description.fil | Fil: Cinat, Gabriela. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Oncología "Ángel H. Roffo"; Argentina | |
| dc.description.fil | Fil: Ranuncolo, Stella Maris. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Oncología; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina | |
| dc.format | application/pdf | es_ES |
| dc.identifier.citation | Sabio Collado, María Victoria; Gandur, María Natalia; Zerga, Marta Elisa; Cugliari, María Silvana; Castro, Mónica; et al.; Assessment of Immune Related Rheumatological Adverse Events in A Monovalent Oncology Center in Argentina; CME Live Publishes Open Access; CME Journal of Clinical Case Report; 2; 12-2025; 1-8 | es_ES |
| dc.identifier.eissn | 3067-7998 | es_ES |
| dc.identifier.institucional | CONICET | |
| dc.identifier.repo | CONICET Digital | |
| dc.identifier.uri | http://hdl.handle.net/11336/301021 | |
| dc.journal.pagination | 1-8 | es_ES |
| dc.journal.pais | Estados Unidos | es_ES |
| dc.journal.title | CME Journal of Clinical Case Report | es_ES |
| dc.journal.volume | 2 | es_ES |
| dc.language.iso | eng | es_ES |
| dc.publisher | CME Live Publishes Open Access | es_ES |
| dc.rights | info:eu-repo/semantics/openAccess | |
| dc.rights.uri | https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ | |
| dc.subject | Immune-Mediated-Rheumatological Adverse Events | es_ES |
| dc.subject | Immune-checkpoints inhibitors | es_ES |
| dc.subject | Oncology patients | es_ES |
| dc.subject | Immune-mediated-Adverse Events | es_ES |
| dc.subject.classification | Oncología | es_ES |
| dc.subject.classification | Medicina Clínica | es_ES |
| dc.subject.classification | CIENCIAS MÉDICAS Y DE LA SALUD | es_ES |
| dc.title | Assessment of Immune Related Rheumatological Adverse Events in A Monovalent Oncology Center in Argentina | es_ES |
| dc.type | info:eu-repo/semantics/article | |
| dc.type | info:ar-repo/semantics/artículo | |
| dc.type | info:eu-repo/semantics/publishedVersion | |
Archivos
Bloque original
Cargando...
- Nombre:
- CONICET_Digital_Nro.102a7f4f-143e-4792-9351-6aa9b398a338_B.pdf
- Tamaño:
- 432.73 KB
- Formato:
- Adobe Portable Document Format